Attached files
| file | filename |
|---|---|
| 8-K - KERYX BIOPHARMACEUTICALS INC | v213829_8-k.htm |
Exhibit 99.1
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and
Year-End 2010 Financial Results
Keryx to Host Investor Conference Call on Wednesday, March 9, 2011
at 8:30am EST
NEW YORK, March 8, 2011 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease (the “Company”), today announced its results for the fourth quarter and year ended December 31, 2010.
At December 31, 2010, the Company had cash, cash equivalents, interest receivable, and investment securities of $28.5 million, as compared to $35.9 million at December 31, 2009.
The net loss for the fourth quarter ended December 31, 2010 was $5.3 million, or $0.09 per share, compared to a net loss of $4.7 million, or $0.08 per share, for the comparable quarter in 2009, representing an increase in net loss of $0.6 million. Other research and development expenses increased by $2.6 million, as compared to the fourth quarter of 2009, principally related to the KRX-0401 (perifosine) and Zerenex Phase 3 clinical programs. The fourth quarter of 2009 included a $1.5 million one-time research and development expense related to a terminated early-stage pipeline product candidate, which accounts for the net increase in other research and development expenses of $1.1 million as compared to the fourth quarter of 2009.
The net loss for the year ended December 31, 2010, was $20.3 million, or $0.34 per diluted share, compared to net income of $10.5 million, or $0.21 per diluted share, for the year ended December 31, 2009. The change in net (loss) income was primarily attributable to a $21.6 million decrease in license revenue and a $3.6 million decrease in other revenue. License revenue in the year ended December 31, 2009 was related to an amendment to the September 2007 sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. (JT/Torii) which eliminated the Company’s significant ongoing obligations included in the original agreement ($18.0 million) and a $3.0 million milestone payment from JT/Torii earned in the first quarter of 2009. Other revenue in the year ended
December 31, 2009 was primarily related to the settlement of a dispute for $3.5 million with the former licensor of Sulonex (sulodexide), in July 2009. The change in net (loss) income was also attributable to a $6.4 million increase in other research and development expenses primarily related to increased expenses for KRX-0401 (perifosine) and Zerenex, as compared to the comparable period last year, related to the Company’s ongoing Phase 3 clinical development programs.
Ron Bentsur, the Company's Chief Executive Officer, commented, "Following another very exciting year, with both of our compounds entering Phase 3 development under SPA agreements with the FDA and the announcement of positive Phase 3 data on Zerenex, we expect to leverage the momentum in 2011 with the anticipated completion of our Phase 3 metastatic colorectal study. On the financial side, we believe we are sufficiently funded to realize the value inherent in our late stage compounds, which we believe represent tremendous commercial opportunities.”
The Company will host an investor conference call tomorrow, Wednesday, March 9, 2011, at 8:30am EST, to discuss the Company’s fourth quarter and year-end 2010 financial results and provide a business outlook for 2011.
In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer
and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.
Cautionary Statement
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our pipeline, including KRX-0401 (perifosine) and Zerenex (ferric citrate); or the effect on our stock value of the other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as
of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com
Source: Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc.
Selected Consolidated Financial Data
(In Thousands, Except Share and Per Share Amounts)
Statements of Operations Information (Unaudited):
|
Three Months Ended December 31,
|
Year Ended December 31,
|
|||||||||||||||
|
2010
|
2009
|
2010
|
2009
|
|||||||||||||
|
REVENUE:
|
||||||||||||||||
|
License revenue
|
$ | -- | $ | -- | $ | -- | $ | 21,616 | ||||||||
|
Service revenue
|
-- | -- | -- | 3 | ||||||||||||
|
Other revenue
|
-- | -- | -- | 3,575 | ||||||||||||
|
TOTAL REVENUE
|
-- | -- | -- | 25,194 | ||||||||||||
|
OPERATING EXPENSES:
|
||||||||||||||||
|
Research and development:
|
||||||||||||||||
|
Non-cash compensation
|
238 | 283 | 1,236 | 1,233 | ||||||||||||
|
Other research and development
|
4,144 | 3,015 | 13,728 | 7,372 | ||||||||||||
|
Total research and development
|
4,382 | 3,298 | 14,964 | 8,605 | ||||||||||||
|
General and administrative:
|
||||||||||||||||
|
Non-cash compensation
|
278 | 219 | 1,237 | 1,867 | ||||||||||||
|
Other general and administrative
|
1,341 | 1,431 | 5,014 | 4,904 | ||||||||||||
|
Total general and administrative
|
1,619 | 1,650 | 6,251 | 6,771 | ||||||||||||
|
TOTAL OPERATING EXPENSES
|
6,001 | 4,948 | 21,215 | 15,376 | ||||||||||||
|
OPERATING (LOSS) INCOME
|
(6,001 | ) | (4,948 | ) | (21,215 | ) | 9,818 | |||||||||
|
OTHER INCOME:
|
||||||||||||||||
|
Interest and other income, net
|
567 | 290 | 764 | 667 | ||||||||||||
|
(LOSS) INCOME FROM CONTINUING OPERATIONS
|
(5,434 | ) | (4,658 | ) | (20,451 | ) | 10,485 | |||||||||
|
Gain from discontinued operations
|
120 | -- | 120 | -- | ||||||||||||
|
NET (LOSS) INCOME
|
$ | (5,314 | ) | $ | (4,658 | ) | $ | (20,331 | ) | $ | 10,485 | |||||
|
NET (LOSS) INCOME PER COMMON SHARE
|
||||||||||||||||
|
Continuing operations
|
$ | (0.09 | ) | $ | (0.08 | ) | $ | (0.34 | ) | $ | 0.21 | |||||
|
Discontinued operations
|
-- | * | -- | -- | * | -- | ||||||||||
|
Basic and diluted net (loss) income
per common share
|
$ | (0.09 | ) | $ | (0.08 | ) | $ | (0.34 | ) | $ | 0.21 | |||||
|
SHARES USED IN COMPUTING NET (LOSS) INCOME PER COMMON SHARE
|
||||||||||||||||
|
Basic
|
61,266,886 | 56,053,536 | 58,987,854 | 49,940,730 | ||||||||||||
|
Diluted
|
61,266,886 | 56,053,536 | 58,987,854 | 50,498,982 | ||||||||||||
|
*Amount less than one cent.
|
||||||||||||||||
Balance Sheet Information:
|
December 31, 2010
|
December 31, 2009*
|
|||||||
|
(Unaudited)
|
||||||||
|
Cash, cash equivalents, interest receivable
|
||||||||
|
and short-term investment securities
|
$ | 28,512 | $ | 34,000 | ||||
|
Long-term investment securities
|
-- | 1,914 | ||||||
|
Total assets
|
32,114 | 40,818 | ||||||
|
Accumulated deficit
|
(341,764 | ) | (321,433 | ) | ||||
|
Stockholders’ equity
|
23,248 | 32,097 | ||||||
* Condensed from audited financial statements